Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy
- Name
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy
- Accession Number
- DBCAT005119
- Description
Not Available
- Drugs
Drug Drug Description Rebastinib Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent. - Drugs & Drug Targets
Drug Target Type